All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Daratumumab granted approval for frontline use in Japan
On 22 August 2019, Genmab A/S (Nasdaq: GMAB) announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan had approved the use of daratumumab in combination with bortezomib, melphalan and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant (ASCT).1
The approval was based on data from the phase III ALCYONE study (NCT02195479) 2 which showed a 50% reduction in the risk of disease progression or death with daratumumab combined with VMP in newly diagnosed patients with MM who were ineligible for ASCT. The MM Hub previously reported the results of this trial when it was presented as a late-breaking abstract at the 2017 American Society of Hematology (ASH) Annual Meeting.
Daratumumab is the first human CD38 monoclonal antibody (mAb) to reach the market in the United States, Europe, and Japan for the treatment of MM.3
Mechanism of action
Daratumumab is an IgG1κ mAb that has a high affinity for CD38, which is overexpressed on MM cells. Daratumumab induces MM cell death through various mechanisms including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis and apoptosis.4
Daratumumab intravenous infusion is indicated for the treatment of adult patients with MM in the United States:5
- In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory MM who have received at least one prior therapy
- In combination with VMP in newly diagnosed patients who are ineligible for ASCT
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
- In combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI)
- As monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent
Daratumumab intravenous infusion is indicated for the treatment of adult patients within Europe:5
- In combination with VMP for the treatment of adult patients with newly diagnosed MM who are ineligible for ASCT
- As monotherapy for the treatment of adult patients with relapsed and refractory MM, whose prior therapy included a PI and an immunomodulatory agent and who demonstrated disease progression on the last therapy
- In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with MM who have received at least one prior therapy
Daratumumab is indicated in Japan:6
- In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adults with relapsed or refractory MM
- In combination with VMP for the treatment of patients with newly diagnosed MM ineligible for ASCT
References